Glucagon-like peptide-1: a potent regulator of food intake in humans
- J-P Gutzwillerb,
- B Gökec,
- J Drewea,
- P Hildebranda,
- S Ketterera,
- D Handschina,
- R Winterhalderb,
- D Conenb,
- C Beglingera
- aDivision of Gastroenterology and Department of Research, University Hospital, CH-4031 Basel, Switzerland, bKantonsspital Aarau, CH-5000 Aarau, Switzerland, cClinical Research Unit for Gastrointestinal Endocrinology, Philipps University of Marburg, D-35033 Marburg, Germany
- Dr C Beglinger.
- Accepted 7 July 1998
Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, not been investigated.
Subjects—Sixteen healthy male subjects were examined in a double blind placebo controlled fashion.
Methods The effect of graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 on food intake and feelings of hunger and satiety was tested in healthy volunteers.
Results Graded GLP-1 infusions resulted in a dose dependent reduction in food intake (maximal inhibition 35%, p<0.001 vcontrol) and a similar reduction in calorie intake (32%; p<0.001). Fluid ingestion was also reduced by GLP-1 (18% reduction, p<0.01). No overt side effects were produced by GLP-1, but subjects experienced less hunger and early fullness in the period before a meal during GLP-1 infusion at the highest dose (p<0.05).
Conclusions Intravenous infusions of GLP-1 decrease spontaneous food intake even at physiological plasma concentrations, implying an important role for GLP-1 in the regulation of the early satiety response in humans.
- glucagon-like peptide-1